(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/217037 A3

(51) International Patent Classification:
C07K 14/725 (2006.01) *A61K 40/32* (2025.01)
A61K 40/11 (2025.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2025/023417

(22) International Filing Date:
07 April 2025 (07.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/631,385	08 April 2024 (08.04.2024)	US
63/644,949	09 May 2024 (09.05.2024)	US
63/653,125	29 May 2024 (29.05.2024)	US
63/716,057	04 November 2024 (04.11.2024)	US
63/729,235	06 December 2024 (06.12.2024)	US

(71) Applicant: **TSCAN THERAPEUTICS, INC.** [US/US]; 830 Winter Street, Waltham, MA 02451 (US).

(72) Inventors: **CHATTOPADHYAY, Shrikanta**; c/o TScan Therapeutics, Inc., 830 Winter Street, Waltham, MA 02451 (US). **MURRAY, Jim**; c/o TScan Therapeutics, Inc., 830 Winter Street, Waltham, MA 02451 (US). **MACBEATH, Gavin**; c/o TScan Therapeutics, Inc., 830 Winter Street, Waltham, MA 02451 (US).

(74) Agent: **CHOI, Philip, S.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
11 December 2025 (11.12.2025)

WO 2025/217037 A3

(54) Title: USE OF BINDING PROTEINS FOR TREATMENT OF SOLID TUMORS

(57) Abstract: The present application encompasses TCRs and combinations of TCRs for treatment of melanoma (e.g., cutaneous melanoma, uveal melanoma, or advanced melanoma), non-small cell lung cancer (NSCLC), head and neck cancer (e.g., non-nasopharyngeal head and neck cancer), sarcoma, thyroid cancer, cervical cancer, ovarian cancer, anal cancer, genital cancer, or anogenital cancer. Due at least in part to the heterogeneity of solid tumor cells, therapies used to treat solid tumors often result in a partial response. The present disclosure includes, among other things, multiplexing of TCRs in a single therapy or therapeutic regimen of engineered T cells.